Update on Intravitreal Injectable Drugs and Dry AMD Treatments
Experts InSight
00:00
FDA Rejection and Uncertainty in Stock Prices
This chapter discusses the recent decline in stock prices for a company that sought FDA approval for a higher dose version of their eye disease treatment. The rejection was due to ongoing review inspection findings of a third party filler. The chapter emphasizes the uncertainty surrounding FDA approvals and the importance of waiting for official confirmation.
Transcript
Play full episode
